Open-Angle Glaucoma - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Open-Angle Glaucoma - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Open-Angle Glaucoma - Pipeline Review, H1 2015', provides an overview of the Open-Angle Glaucoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Open-Angle Glaucoma Overview 8
Therapeutics Development 9
Pipeline Products for Open-Angle Glaucoma - Overview 9
Pipeline Products for Open-Angle Glaucoma - Comparative Analysis 10
Open-Angle Glaucoma - Therapeutics under Development by Companies 11
Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes 13
Open-Angle Glaucoma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Open-Angle Glaucoma - Products under Development by Companies 17
Open-Angle Glaucoma - Products under Investigation by Universities/Institutes 18
Open-Angle Glaucoma - Companies Involved in Therapeutics Development 19
Aerie Pharmaceuticals, Inc. 19
Allergan, Inc. 20
Amakem NV 21
Asahi Kasei Pharma Corp. 22
Bausch & Lomb Incorporated 23
F. Hoffmann-La Roche Ltd. 24
High Point Pharmaceuticals, LLC 25
Inotek Pharmaceuticals Corporation 26
Ocular Therapeutix, Inc. 27
Ono Pharmaceutical Co., Ltd. 28
Otsuka Holdings Co., Ltd. 29
Oxford BioMedica plc 30
Santen Pharmaceutical Co., Ltd. 31
Sun Pharmaceutical Industries Limited 32
Sylentis S.A. 33
Open-Angle Glaucoma - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
(carteolol hydrochloride + latanoprost) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(dorzolamide hydrochloride + latanoprost) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(latanoprost + trabodenoson) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AMA-0076 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
AR-13324 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ATS-8535 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
bamosiran - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
bimatoprost SR - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
DE-117 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Glaucoma-GT - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
HPP-851 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
latanoprost - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
latanoprost - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
latanoprost SR - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
latanoprostene bunod - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ONO-9054 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
OPA-6566 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
R-807 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
RO-5093151 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecule for Glaucoma - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
trabodenoson - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
travoprost SR - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Open-Angle Glaucoma - Recent Pipeline Updates 71
Open-Angle Glaucoma - Dormant Projects 79
Open-Angle Glaucoma - Discontinued Products 80
Open-Angle Glaucoma - Product Development Milestones 81
Featured News & Press Releases 81
Mar 13, 2012: NicOx, Bausch + Lomb's Glaucoma Candidate BOL-303259-X Meets Primary Endpoint In Phase IIb Study 81
Nov 28, 2011: NicOx Announces Completion Of Patient Recruitment In Glaucoma Study 82
Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System 82
Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System 83
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86

List of Tables
Number of Products under Development for Open-Angle Glaucoma, H1 2015 9
Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Open-Angle Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H1 2015 19
Open-Angle Glaucoma - Pipeline by Allergan, Inc., H1 2015 20
Open-Angle Glaucoma - Pipeline by Amakem NV, H1 2015 21
Open-Angle Glaucoma - Pipeline by Asahi Kasei Pharma Corp., H1 2015 22
Open-Angle Glaucoma - Pipeline by Bausch & Lomb Incorporated, H1 2015 23
Open-Angle Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 24
Open-Angle Glaucoma - Pipeline by High Point Pharmaceuticals, LLC, H1 2015 25
Open-Angle Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H1 2015 26
Open-Angle Glaucoma - Pipeline by Ocular Therapeutix, Inc., H1 2015 27
Open-Angle Glaucoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 28
Open-Angle Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 29
Open-Angle Glaucoma - Pipeline by Oxford BioMedica plc, H1 2015 30
Open-Angle Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 31
Open-Angle Glaucoma - Pipeline by Sun Pharmaceutical Industries Limited, H1 2015 32
Open-Angle Glaucoma - Pipeline by Sylentis S.A., H1 2015 33
Assessment by Monotherapy Products, H1 2015 34
Assessment by Combination Products, H1 2015 35
Number of Products by Stage and Target, H1 2015 37
Number of Products by Stage and Mechanism of Action, H1 2015 39
Number of Products by Stage and Route of Administration, H1 2015 41
Number of Products by Stage and Molecule Type, H1 2015 43
Open-Angle Glaucoma Therapeutics - Recent Pipeline Updates, H1 2015 71
Open-Angle Glaucoma - Dormant Projects, H1 2015 79
Open-Angle Glaucoma - Discontinued Products, H1 2015 80